A Review of the Safety and Adverse Event Profile of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide

ConclusioniGlarLixi has a safety profile that is consistent with that of its two active components insulin glargine and lixisenatide, with no signals for pancreatitis or thyroid C  cell tumors, and no black-box warning for iGlarLixi. There were no unexpected safety findings; iGlarLixi had beneficial effects on glycemic control, with no increased risk of hypoglycemia, despite a greater glycated hemoglobin A1c reduction. In addition, there were also fewer gastrointestinal AEs associated with iGlarLixi compared with lixisenatide alone.FundingSanofi US Inc.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research

Related Links:

ConclusionsFindings suggest that self-harm behavior and psychiatric disorders are associated with increased ED utilization for subsequent chronic disease-related ED utilization. Chronic disease among adolescent psychiatric patients should be attended to, potentially involving new models of clinical follow-up care.
Source: Journal of Adolescence - Category: Child Development Source Type: research
In this study, to estimate the states that are not directly available from the Bergman minimal model a high-order sliding mode observer is proposed. Then fractional calculus is combined with sliding mode control (SMC) for blood glucose regulation to create more robustness performance and make more degree of freedom and flexibility for the proposed method. Then an adaptive fractional-order SMC is proposed. The adaptive SMC protect controller against disturbance and uncertainties while the fractional calculus provides robust performance. Numerical simulation verifies that the proposed controllers have better performance in t...
Source: IET Systems Biology - Category: Biology Source Type: research
This paper deals with the design of robust observer based output feedback control law for the stabilisation of an uncertain nonlinear system and subsequently apply the developed method for the regulation of plasma glucose concentration in Type 1 diabetes (T1D) patients. The principal objective behind the proposed design is to deal with the issues of intra-patient parametric variation and non-availability of all state variables for measurement. The proposed control technique for the T1D patient model is based on the attractive ellipsoid method (AEM). The observer and controller conditions are obtained in terms of linear mat...
Source: IET Systems Biology - Category: Biology Source Type: research
[Guardian] Researchers are unanimous that talc or talcum powder can cause lung, ovarian, stomach and endometrial (uterine) cancers. They said talc consisting of asbestos is generally accepted as being able to cause cancer if it is inhaled or/and used regularly in the genital area. Evidence on asbestos-free talc is however less clear.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
Could a simple blood test catch cancer before symptoms appear?Nicola Davis goes beyond the hype and investigates the future of blood diagnostics and cancerA blood test that could detect cancer earlier than current methods has long been a dream of oncologists. The hope is that these “liquid biopsies” could save countless lives by diagnosing cancer before symptoms show. They’re less invasive, quicker and easier than what is available now.However, this area of research has been plagued with hype. This happened most notably when a Silicon Valley startup –Theranos– allegedlyduped investors out of h...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Science Cancer research Medical research Source Type: news
This study is registered with ClinicalTrials.gov, number NCT02465515.FindingsPatients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-trea...
Source: The Lancet - Category: General Medicine Source Type: research
AbstractPurpose of ReviewGlucagon-like peptide-1 receptor agonists (GLP-1 RAs) have positive effects on weight loss, blood pressure, hyperlipidemia, and glycemic control. They exhibit a broad range of effects on the cardiovascular system that are independent of changes in blood glucose. Cardiovascular outcome trials have demonstrated safety of GLP-1 RAs but results for cardiovascular efficacy were varied. The aim of the present review is the assessment of the effects of GLP-1 RAs on cardiovascular risk factors, and major cardiovascular events.Recent FindingsUse of GLP-1 RAs was associated with relative risk reduction in ca...
Source: Current Diabetes Reports - Category: Endocrinology Source Type: research
Publication date: Available online 6 December 2017 Source:The Lancet Diabetes & Endocrinology Author(s): M Angelyn Bethel, Rishi A Patel, Peter Merrill, Yuliya Lokhnygina, John B Buse, Robert J Mentz, Neha J Pagidipati, Juliana C Chan, Stephanie M Gustavson, Nayyar Iqbal, Aldo P Maggioni, Peter Öhman, Neil R Poulter, Ambady Ramachandran, Bernard Zinman, Adrian F Hernandez, Rury R Holman Background Glucagon-like peptide-1 (GLP-1) receptor agonists are effective glucose-lowering drugs. Findings from cardiovascular outcome trials showed cardiovascular safety of GLP-1 receptor agonists, but results for cardiovascular...
Source: The Lancet Diabetes and Endocrinology - Category: Endocrinology Source Type: research
CONCLUSION: GLP-1 RA therapy in the context of individualized, patient-centered care continues to be supported by current literature. GLP-1 RA therapy provides robust glycemic control, blood pressure reduction, and weight loss, but studies are still needed to address concerns about tolerability and safety, including pancreatitis and cancer. PMID: 26694823 [PubMed - as supplied by publisher]
Source: Current Diabetes Reviews - Category: Endocrinology Authors: Tags: Curr Diabetes Rev Source Type: research
This article aims to provide a comprehensive overview of current knowledge regarding the possible positive effects of GLP-1 RA in the treatment of T1DM patients. PMID: 26438316 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Tags: Curr Pharm Des Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Gastroenterology | Heart | Insulin | Lantus | Pancreas | Pancreatic Cancer | Pancreatitis | Study | Thyroid | Thyroid Cancer | Warnings